Study of GNX102 in Patients With Advanced Solid Tumors

Summary

GNX102 is a humanized monoclonal antibody (mAb), an engineered biotechnology product, developed by GlycoNex that targets certain cancer cells by binding with high affinity to specific structures on cancer cells. Specifically, GNX102 binds to novel glycan structures caused by glycosylation changes in tumors. Patients with epithelial origin cancers that have a likelihood of GNX102 targeted antigen expression based on previous studies, including colorectal, hepatocellular, non-small cell lung, gastric, breast, pancreatic, cutaneous, acral, or mucosal melanoma, esophageal, prostate, and epithelial uterine cancers, can be screened for enrollment in the study.

Timeline

Start

2020-07-29

Primary completion

2023-07-26

Completion

2023-07-26

Outcome

Outcome not reported

Stopped (Business): “Maximum tolerated dose reached; expansion phase not performed per Sponsor business decision.”

Drugs

Indications